Table 1 Baseline characteristics of patients with and without post-procedural AKI after urgent percutaneous coronary intervention identified between January 2008 – December 2013
|  |  | 48 h post-PCI |  | |
|---|---|---|---|---|
| Â | Overall | No AKI | AKI | D-value |
|  | (N = 7250) | (N = 6944) | (N = 306) | |
Sociodemographic characteristics | ||||
Mean (SD) age, yr | 67 (12) | 67 (12) | 72 (12) | 0.47 |
Women, No. (%) | 2074 (29) | 1949 (28) | 125 (41) | 0.27 |
Race, No. (%) | ||||
 White | 4472 (62) | 4300 (62) | 172 (56) | 0.23 |
 Black/African American | 378 (5) | 358 (5) | 20 (67) |  |
 Asian/Pacific Islander | 1146 (16) | 1108 (16) | 38 (12) |  |
 Other/Unknown | 1254 (17) | 1178 (17) | 76 (25) |  |
Hispanic ethnicity, No. (%) | 921 (13) | 865 (12) | 56 (18) | 0.16 |
Index PCI event, No. (%) | Â | Â | Â | 0.24 |
 No incident MI | 1280 (18) | 1248 (18) | 32 (11) |  |
 NSTEMI | 4486 (62) | 4283 (62) | 203 (66) |  |
 STEMI | 1484 (20) | 1413 (20) | 71 (23) |  |
Medical history, No. (%) | ||||
 Acute myocardial infarction | 501 (7) | 471 (7) | 30 (10) | 0.11 |
 Unstable angina | 77 (1) | 74 (1) | 3 (1) | 0.01 |
 Coronary artery bypass graft | 118 (1) | 117 (1) | 1 (0) | 0.14 |
 Percutaneous coronary intervention | 574 (8) | 553 (8) | 21 (7) | 0.04 |
 Atrial fibrillation or flutter | 581 (8) | 543 (8) | 38 (12) | 0.15 |
 Ischemic stroke/transient ischemic attack | 235 (3) | 218 (3) | 17 (6) | 0.12 |
 Heart failure | 729 (10) | 665 (10) | 64 (21) | 0.32 |
 Peripheral artery disease | 205 (3) | 180 (3) | 25 (8) | 0.25 |
 Hypertension | 5182 (72) | 4905 (71) | 277 (91) | 0.52 |
 Dyslipidemia | 5520 (76) | 5250 (76) | 270 (88) | 0.33 |
 Diabetes mellitus | 2397 (33) | 2221 (32) | 176 (58) | 0.53 |
 Hypothyroidism | 848 (12) | 794 (11) | 54 (18) | 0.18 |
 Chronic lung disease | 1848 (26) | 1769 (26) | 79 (26) | 0.01 |
 Diagnosed dementia | 171 (2) | 163 (2) | 8 (3) | 0.02 |
 Diagnosed depression | 1003 (14) | 942 (14) | 61 (20) | 0.17 |
Baseline medication, No. (%) | ||||
 ACE inhibitor | 2520 (35) | 2414 (35) | 106 (35) | 0.00 |
 Angiotensin II receptor blocker | 1035 (14) | 963 (14) | 72 (24) | 0.25 |
 Beta blocker | 3364 (46) | 3164 (46) | 200 (65) | 0.41 |
 Calcium channel blocker | 1425 (20) | 1315 (19) | 110 (36) | 0.39 |
 Diuretic | 2441 (34) | 2281 (33) | 160 (52) | 0.40 |
 Aldosterone receptor antagonist | 99 (1) | 93 (1) | 6 (2) | 0.05 |
 Alpha blocker | 772 (11) | 712 (10) | 60 (20) | 0.26 |
 Statin | 3980 (55) | 3781 (54) | 199 (65) | 0.22 |
 Other lipid-lowering agent | 478 (7) | 454 (7) | 24 (8) | 0.05 |
 Non-aspirin antiplatelet agent | 713 (10) | 657 (10) | 56 (18) | 0.26 |
 Anticoagulant | 384 (5) | 362 (5) | 22 (7) | 0.08 |
 Diabetic therapy | 1390 (19) | 1259 (18) | 131 (43) | 0.56 |
Laboratory results | ||||
Qualifying estimated glomerular filtration rate, ml/min/1.73 m2, No. (%) |  |  |  | 0.92 |
  > 150 | 1 (0) | 1 (0) | 0 (0) |  |
 90–150 | 1803 (25) | 1775 (26) | 28 (9) |  |
 60–89 | 3571 (49) | 3481 (50) | 90 (29) |  |
 45–59 | 1138 (16) | 1069 (15) | 69 (23) |  |
 30–44 | 569 (8) | 492 (7) | 77 (25) |  |
 15–29 | 168 (2) | 126 (2) | 42 (14) |  |
Documented proteinuria, No. (%) | ||||
 Yes | 2036 (28) | 1850 (27) | 186 (61) | 0.73 |